Recurrent Malignant Glioma Clinical Trial
Official title:
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Verified date | April 2024 |
Source | Oblato, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease. Patients with unequivocal recurrence (first or greater) established by MRI and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.
Status | Active, not recruiting |
Enrollment | 57 |
Est. completion date | January 31, 2025 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Confirmed Glioblastoma based on histopathology or molecular profile analysis (WHO Grade IV), following primary treatment with TMZ and radiotherapy (minimum of 50 Gy) and at least two cycles of maintenance TMZ (5 days of a 28 day cycle) as first-line or second-line treatment with another treatment regimen, excluding bevacizumab. 2. Patients must have medical records available documenting O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status analysis or must have tumor tissue samples available from prior GBM surgery or open biopsy for MGMT status determination. 3. For patients with unresected recurrent tumor, unequivocal radiographic evidence of tumor progression by MRI. These patients must have at least one measurable lesion. 4. Patients with recent resection of recurrent viable tumor are eligible following post-operative MRI perfusion scan with or without measurable lesions. 5. No more than two prior lines of therapy for glioblastoma. Any second-line therapy is acceptable, excluding bevacizumab as second line. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 7. Full recovery (= grade 1) from the toxic effects. 8. Adequate renal, liver and bone marrow function: - Hemoglobin >9.0 g/dL - Leukocytes >3,000/mcL - Absolute neutrophil count >1,500/mcL - Platelets >100,000/mcL - Total bilirubin = 1.5 × upper limit of normal (ULN) - AST (SGOT) / ALT (SGPT) =2.5 × ULN - Creatinine clearance = 60 mL/min 9. Patients must be =18 years of age Exclusion Criteria: 1. Early discontinuation of TMZ in prior line due to treatment related Adverse events (AEs). 2. Second primary malignancy expected to require treatment within a 6 month period (except adequately treated basal cell carcinoma of the skin). 3. Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry. 4. Have received chemotherapeutic agents (including temozolomide) within 28 days or within 5 half-lives for non-cytotoxic agents (whichever is shorter) of study entry 5. Serious concomitant systemic disorders 6. Patients with abnormal sodium, potassium, or creatinine levels = grade 2. 7. Patients with prothrombin time/partial thromboplastin time (PT/PTT) or International normalized ratio (INR) above the ULN. 8. Inability to comply with protocol or study procedures. 9. Patients who have received bevacizumab for recurrent glioblastoma or are planning to initiate treatment with bevacizumab for tumor necrosis. (Past treatment with bevacizumab for tumor necrosis is acceptable). 10. Patients receiving or planning to initiate treatment with the tumor treating fields device (Optune®) (Optune® prior to enrollment is permitted). |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Swedish Medical Center | Englewood | Colorado |
United States | University of Iowa | Iowa City | Iowa |
United States | Norton Healthcare | Louisville | Kentucky |
United States | The University of Oklahoma | Oklahoma City | Oklahoma |
United States | AdventHealth Orlando | Orlando | Florida |
United States | St. Joseph's Hospital and Medical Center | Phoenix | Arizona |
United States | Lifespan Office of Research | Providence | Rhode Island |
United States | Providence Saint John's Health Center - John Wayne Cancer Institute | Santa Monica | California |
United States | St. Joseph Hospital of Orange | Seattle | Washington |
United States | The University of Toledo | Toledo | Ohio |
United States | Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Oblato, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidents of Adverse Events during the subjects are taking OKN-007 with Temozolomide | Evaluate incidents of Adverse Events during the subjects are taking OKN-007 with Temozolomide. Adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). | Through study completion up to 24 months | |
Primary | Number of subjects with decreased neurological function | Neurologic function assessed by Neurologic Assessment in Neuro-Oncology (NANO) scale. The NANO Scale evaluates 9 major domains of neurologic function, with each domain being scored on a range from 0 (no deficits) to 2 or 3 (maximum deficits). | Change from baseline at Day 1 of each 28 day cycle | |
Primary | Number of subjects with decreased performance | Number of participants with decreased performance assessed by Eastern Oncology Cooperative Group (ECOG) scale. Minimum 0 (normal function) and maximum 4 (maximum disability). | Change from baseline at Day 1 of each 28 day cycle | |
Primary | Overall Survival (OS) rate | Proportion of subjects who are alive after six months of starting treatment. OS is defined as the time from first treatment dose until date of death due to any cause. | 6 months | |
Secondary | Radiographic response rate | To determine the objective response rate to study therapy using Radiographic Assessment in Neuro-Oncology (RANO) criteria. | 24 months | |
Secondary | Progression Free Survival (PFS) rate | Proportion of subjects who are alive and progression free after six months of starting treatment. PFS is defined as the time from first treatment dose until objective tumor progression on the RANO criteria or death. | 6 months | |
Secondary | Cmax of OKN-007 in blood plasma | The sample will be collected at 10 time points during 24 hours after OKN-007 administration. | Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle) | |
Secondary | AUC of OKN-007 in blood plasma | The sample will be collected at 10 time points during 24 hours after OKN-007 administration. | Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle) | |
Secondary | Tmax of OKN-007 in blood plasma | The sample will be collected at 10 time points during 24 hours after OKN-007 administration. | Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle) | |
Secondary | Cmax of Temozolomide in blood plasma | The sample will be collected at 8 time points during 24 hours after Temozolomide administration. | Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle) | |
Secondary | AUC of Temozolomide in blood plasma | The sample will be collected at 8 time points during 24 hours after Temozolomide administration. | Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle) | |
Secondary | Tmax of Temozolomide in blood plasma | The sample will be collected at 8 time points during 24 hours after Temozolomide administration. | Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05045027 -
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
|
Early Phase 1 | |
Recruiting |
NCT04323046 -
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
|
Phase 1 | |
Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT03598244 -
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
|
Phase 1 | |
Recruiting |
NCT05278208 -
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03213665 -
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT04320888 -
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT05139056 -
Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
|
Phase 1 | |
Active, not recruiting |
NCT02208362 -
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
|
Phase 1 | |
Active, not recruiting |
NCT02192359 -
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
Unknown status |
NCT01144988 -
Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma
|
Phase 2 | |
Active, not recruiting |
NCT03210714 -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT04195555 -
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Recruiting |
NCT05540873 -
A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)
|
Phase 1 | |
Completed |
NCT01904123 -
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
|
Phase 1 | |
Active, not recruiting |
NCT02658279 -
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
|
N/A | |
Withdrawn |
NCT04521946 -
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
|
Phase 1 | |
Recruiting |
NCT04214392 -
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
|
Phase 1 | |
Recruiting |
NCT03896568 -
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
|
Phase 1 | |
Active, not recruiting |
NCT01672463 -
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
|
Phase 1 |